×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RDY – dr. reddy's laboratories ltd (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RDY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/1
06:31 am
rdy
Dr. Reddy's Laboratories (NYSE:RDY) was upgraded by analysts at Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
Low
Report
Dr. Reddy's Laboratories (NYSE:RDY) was upgraded by analysts at Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
1/30
08:51 am
rdy
Coya Therapeutics raises $11.1M in private placement led by Dr. Reddy's [Seeking Alpha]
Low
Report
Coya Therapeutics raises $11.1M in private placement led by Dr. Reddy's [Seeking Alpha]
1/25
08:31 pm
rdy
Dr Reddy's Laboratories Ltd (RDY) Q3 2026 Earnings Call Highlights: Navigating Growth Amidst ... [Yahoo! Finance]
Low
Report
Dr Reddy's Laboratories Ltd (RDY) Q3 2026 Earnings Call Highlights: Navigating Growth Amidst ... [Yahoo! Finance]
1/21
11:41 pm
rdy
Dr. Reddy's GAAP EPS of ?14.52, revenue of ?87.27B [Seeking Alpha]
Low
Report
Dr. Reddy's GAAP EPS of ?14.52, revenue of ?87.27B [Seeking Alpha]
1/21
04:27 pm
rdy
Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript [Seeking Alpha]
Low
Report
Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript [Seeking Alpha]
1/21
12:41 pm
rdy
Dr. Reddy's Laboratories Q3 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Dr. Reddy's Laboratories Q3 Earnings Call Highlights [Yahoo! Finance]
1/17
04:31 pm
rdy
Dr. Reddy's Laboratories (NYSE:RDY) was downgraded by analysts at Weiss Ratings from a "buy (b-)" rating to a "hold (c+)" rating.
Low
Report
Dr. Reddy's Laboratories (NYSE:RDY) was downgraded by analysts at Weiss Ratings from a "buy (b-)" rating to a "hold (c+)" rating.
1/14
08:49 am
rdy
Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.
Low
Report
Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.
Date
Time
Symbol
Company Name
Action
%Chg
1/22/2026
04:05 pm
rdy
dr. reddy's laboratories ltd
BEAT
Report
-0.2%
dr. reddy's laboratories ltd
1/21/2026
04:06 pm
rdy
dr. reddy's laboratories ltd
BEAT
Report
3.2%
dr. reddy's laboratories ltd
1/21/2026
07:06 am
rdy
dr. reddy's laboratories ltd
BEAT
Report
3.3%
dr. reddy's laboratories ltd
7/24/2025
04:01 pm
rdy
dr. reddy's laboratories ltd
BEAT
Report
0.4%
dr. reddy's laboratories ltd
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/2
07:40 am
rdy
Form 6-K DR REDDYS LABORATORIES For: Feb 02
Low
Report
Form 6-K DR REDDYS LABORATORIES For: Feb 02
1/28
06:15 am
rdy
Form 6-K DR REDDYS LABORATORIES For: Jan 27
Low
Report
Form 6-K DR REDDYS LABORATORIES For: Jan 27
1/26
06:05 am
rdy
Form 6-K DR REDDYS LABORATORIES For: Jan 24
Low
Report
Form 6-K DR REDDYS LABORATORIES For: Jan 24
1/22
06:38 am
rdy
Form 6-K DR REDDYS LABORATORIES For: Jan 21
Low
Report
Form 6-K DR REDDYS LABORATORIES For: Jan 21
1/21
12:58 pm
rdy
Form 6-K DR REDDYS LABORATORIES For: Jan 21
Low
Report
Form 6-K DR REDDYS LABORATORIES For: Jan 21
1/21
12:28 pm
rdy
Form 6-K DR REDDYS LABORATORIES For: Jan 21
Low
Report
Form 6-K DR REDDYS LABORATORIES For: Jan 21
1/21
11:22 am
rdy
Form 6-K DR REDDYS LABORATORIES For: Jan 21
Low
Report
Form 6-K DR REDDYS LABORATORIES For: Jan 21
1/15
06:10 am
rdy
Form 6-K DR REDDYS LABORATORIES For: Jan 14
Low
Report
Form 6-K DR REDDYS LABORATORIES For: Jan 14
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/13
Dr.Reddy's Laboratories Ltd (NYSE: RDY) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating.
6.2%
1/27 Form 6-K DR REDDYS LABORATORIES For: Jan 27 5.3%
4/9 Form SC 13G/A DR REDDYS LABORATORIES Filed by: BlackRock Inc. 4.8%
3/20 Dr. Reddy's launches pyrimethamine tablets in U.S. [Seeking Alpha] 3.9%
3/17 Dr. Reddy's Laboratories announces the launch of Ziprasidone Mesylate for Injection in the U.S. Market 3.0%
10/23 Dr. Reddy’s Confirms Its Voluntary Nationwide Recall of All Ranitidine Products in the U.S. Market 2.8%
7/29 Dr. Reddy's Laboratories Limited 2020 Q1 - Results - Earnings Call Slides [Seeking Alpha] 2.8%
9/11 Hazmat situation reported at Dr. Reddy's New York facility [Seeking Alpha] 2.8%
5/20 Q4/2019 3/31/2019 EPS 26.160 ZacksConsensus N/A ActVsEst N/A - N/A 2.7%
9/9 Form SC 13G DR REDDYS LABORATORIES Filed by: COMMONWEALTH BANK OF AUSTRALIA 2.4%
1/27 Form 6-K DR REDDYS LABORATORIES For: Jan 27 5.3%
4/9 Form SC 13G/A DR REDDYS LABORATORIES Filed by: BlackRock Inc. 4.8%
3/20 Dr. Reddy's launches pyrimethamine tablets in U.S. [Seeking Alpha] 3.9%
3/17 Dr. Reddy's Laboratories announces the launch of Ziprasidone Mesylate for Injection in the U.S. Market 3.0%
10/23 Dr. Reddy’s Confirms Its Voluntary Nationwide Recall of All Ranitidine Products in the U.S. Market 2.8%
7/29 Dr. Reddy's Laboratories Limited 2020 Q1 - Results - Earnings Call Slides [Seeking Alpha] 2.8%
9/11 Hazmat situation reported at Dr. Reddy's New York facility [Seeking Alpha] 2.8%
5/20 Q4/2019 3/31/2019 EPS 26.160 ZacksConsensus N/A ActVsEst N/A - N/A 2.7%
9/9 Form SC 13G DR REDDYS LABORATORIES Filed by: COMMONWEALTH BANK OF AUSTRALIA 2.4%
TOP News Decliners
3/12
Form 6-K DR REDDYS LABORATORIES For: Mar 12
-6.6%
5/17 Q4/2019 3/31/2019 EPS 26.160 ZacksConsensus N/A ActVsEst N/A - N/A -6.0%
3/16 Form 6-K DR REDDYS LABORATORIES For: Mar 14 -4.6%
7/29 Dr. Reddy’s Q1 FY20 Financial Results -3.3%
7/29 Q1/2020 6/30/2019 EPS 39.910 ZacksConsensus N/A ActVsEst N/A - N/A -2.9%
7/23 Form 6-K DR REDDYS LABORATORIES For: Jul 23 -2.5%
2/27 Dr. Reddy's Laboratories Announces the First Generic Launch of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets in the U.S. Market -2.3%
5/17 Q4/2019 3/31/2019 EPS 26.160 ZacksConsensus N/A ActVsEst N/A - N/A -1.9%
10/23 Dr. Reddy's is recalling some products used to treat heartburn [CNN] -1.8%
11/22 Dr. Reddy's Laboratories announces launch of Doxercalciferol Injection in the U.S. Market -1.7%
5/17 Q4/2019 3/31/2019 EPS 26.160 ZacksConsensus N/A ActVsEst N/A - N/A -6.0%
3/16 Form 6-K DR REDDYS LABORATORIES For: Mar 14 -4.6%
7/29 Dr. Reddy’s Q1 FY20 Financial Results -3.3%
7/29 Q1/2020 6/30/2019 EPS 39.910 ZacksConsensus N/A ActVsEst N/A - N/A -2.9%
7/23 Form 6-K DR REDDYS LABORATORIES For: Jul 23 -2.5%
2/27 Dr. Reddy's Laboratories Announces the First Generic Launch of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets in the U.S. Market -2.3%
5/17 Q4/2019 3/31/2019 EPS 26.160 ZacksConsensus N/A ActVsEst N/A - N/A -1.9%
10/23 Dr. Reddy's is recalling some products used to treat heartburn [CNN] -1.8%
11/22 Dr. Reddy's Laboratories announces launch of Doxercalciferol Injection in the U.S. Market -1.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: